Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. 1996

M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Parkville, Victoria, Australia.

1. Autoradiographic binding studies have shown that the AT1 receptor is the predominant angiotensin II (AngII) receptor subtype in the central nervous system (CNS). Major sites of AT1 receptors are the lamina terminalis, hypothalamic paraventricular nucleus, the lateral parabrachial nucleus, rostral and caudal ventrolateral medulla, nucleus of the solitary tract and the intermediolateral cell column of the thoraco-lumbar spinal cord. 2. While there are differences between species, AT2 receptors are found mainly in the cerebellum, inferior olive and locus coeruleus of the rat. 3. Circulating AngII acts on AT1 receptors in the subfornical organ and organum vasculosum of the lamina terminalis (OVLT) to stimulate neurons that may have a role in initiating water drinking. 4. Centrally administered AngII may act on AT1 receptors in the median preoptic nucleus and elsewhere to induce drinking, sodium appetite, a sympathetic vasoconstrictor response and vasopressin secretion. 5. Recent evidence shows that centrally administered AT1 antagonists inhibit dipsogenic, natriuretic, pressor and vasopressin secretory responses to intracerebroventricular infusion of hypertonic saline. This suggests that n angiotensinergic neural pathway has a role in osmoregulatory responses. 6. Central angiotensinergic pathways which include neural inputs to the rostral ventrolateral medulla may use AT1 receptors and play a role in the function of sympathetic pathways maintaining arterial pressure.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008159 Lumbar Vertebrae VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE. Vertebrae, Lumbar
D008526 Medulla Oblongata The lower portion of the BRAIN STEM. It is inferior to the PONS and anterior to the CEREBELLUM. Medulla oblongata serves as a relay station between the brain and the spinal cord, and contains centers for regulating respiratory, vasomotor, cardiac, and reflex activities. Accessory Cuneate Nucleus,Ambiguous Nucleus,Arcuate Nucleus of the Medulla,Arcuate Nucleus-1,External Cuneate Nucleus,Lateral Cuneate Nucleus,Nucleus Ambiguus,Ambiguus, Nucleus,Arcuate Nucleus 1,Arcuate Nucleus-1s,Cuneate Nucleus, Accessory,Cuneate Nucleus, External,Cuneate Nucleus, Lateral,Medulla Oblongatas,Nucleus, Accessory Cuneate,Nucleus, Ambiguous,Nucleus, External Cuneate,Nucleus, Lateral Cuneate
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D004302 Dorsomedial Hypothalamic Nucleus An aggregation of cells in the middle hypothalamus dorsal to the ventromedial nucleus and bordering the THIRD VENTRICLE. Hypothalamic Nucleus, Dorsomedial,Nucleus, Dorsomedial Hypothalamic
D004326 Drinking The consumption of liquids. Water Consumption,Water Intake,Drinkings
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013356 Subfornical Organ A structure, situated close to the intraventricular foramen, which induces DRINKING BEHAVIOR after stimulation with ANGIOTENSIN II. Organum Subfornicale,Organ, Subfornical,Organs, Subfornical,Organum Subfornicales,Subfornical Organs,Subfornicale, Organum,Subfornicales, Organum

Related Publications

M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
December 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
October 1997, Japanese circulation journal,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
May 2006, Histology and histopathology,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
February 1993, Brain research,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
January 1999, Journal of the American Society of Nephrology : JASN,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
January 1996, Blood pressure. Supplement,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
January 2005, Regulatory peptides,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
August 1997, The American journal of physiology,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
March 1998, Journal of cardiovascular pharmacology,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
July 1998, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!